- Home
- ADCT
ADCT
ADC Therapeutics SA
as 11-21-2024 12:30pm EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 285.2M | IPO Year: | 2020 |
| Target Price: | $7.33 | AVG Volume (30 days): | 437.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $6.04 | Next Earning Date: | 11-07-2024 |
| Revenue: | $70,717,000 | Revenue Growth: | -42.30% |
| Revenue Growth (this year): | 6.66% | Revenue Growth (next year): | 16.38% |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
GuruFocus.com
7 days ago
BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ...
Simply Wall St.
12 days ago
ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations
Benzinga
13 days ago
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
Zacks
14 days ago
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
PR Newswire
14 days ago
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
Zacks
15 days ago
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
GuruFocus.com
15 days ago
What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings
PR Newswire
16 days ago
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.